6 citations,
July 2022 in “Journal of health economics and outcomes research” Adolescents with severe alopecia incur significantly higher healthcare costs.
3 citations,
April 2022 in “Microorganisms” People with severe hair loss (Alopecia Areata) have different scalp bacteria than healthy people, which might help predict the condition's progress.
1 citations,
April 2019 in “Acta Medica Philippina” Azathioprine may help treat severe alopecia areata, but more research is needed.
March 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
December 2020 in “Rossijskij žurnal kožnyh i veneričeskih boleznej” People with severe alopecia areata often have lower vitamin D levels and may have other autoimmune or allergic conditions.
July 2020 in “Benha Medical Journal” People with severe Alopecia Areata have higher levels of TGF-β1, which may play a role in the condition.
April 2016 in “Journal of The American Academy of Dermatology” The study found that severe alopecia areata affects any age, treatments often give temporary results, and some factors predict worse outcomes.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
18 citations,
January 2017 in “Annals of dermatology/Annals of Dermatology” Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.
11 citations,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
9 citations,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
8 citations,
July 2018 in “The Journal of Dermatology” Current corticosteroid pulse therapy is not very effective for severe rapidly progressive alopecia areata.
7 citations,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
6 citations,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
4 citations,
January 2022 in “Drug design, development and therapy” Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
December 2023 in “European journal of dermatology/EJD. European journal of dermatology” More effective treatments are needed for severe alopecia areata.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
March 2023 in “Photodiagnosis and Photodynamic Therapy” Low vitamin D levels are linked to severe and active alopecia areata.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
44 citations,
August 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Methotrexate is a promising and safe treatment for severe alopecia areata, with better results when combined with corticosteroids.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
29 citations,
March 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.
5 citations,
May 2018 in “Journal of the American Academy of Dermatology” Lower vitamin D levels might be linked to more severe alopecia areata, but more research is needed to understand if vitamin D can help treat it.
4 citations,
November 2021 in “Journal of Clinical Medicine” Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.